Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.43 |
| ▸ | PARP15 | Q460N3 | 1/20 | 0.40 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.40 |
| ▸ | PARP2 | Q9UGN5 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 2/20 | 0.40 |
| ▸ | KAT6A | Q92794 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | DGAT1 | O75907 | 7/20 | 0.39 |
| ▸ | GCGR | P47871 | 1/20 | 0.39 |
| ▸ | ACSL1 | P33121 | 1/20 | 0.39 |
| ▸ | PDE4A | P27815 | 2/20 | 0.39 |
| ▸ | PDE4B | Q07343 | 2/20 | 0.39 |
| ▸ | PDE4C | Q08493 | 2/20 | 0.39 |
| ▸ | PDE4D | Q08499 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10184929 | 0.94 | HRH3 (0.40) | NR1H4NPC1DGAT1 | |
| SCHEMBL10185185 | 0.91 | NPC1 (0.50) | NPC1RAB9ADGAT1 | |
| SCHEMBL10185129 | 0.89 | PARP15 (0.48) | NR1H4PARP15PARP10PARP2NPC1 | |
| SCHEMBL10186424 | 0.87 | ALDH1A1 (0.46) | NPC1DGAT1ACSL1 | |
| SCHEMBL10186453 | 0.86 | DGAT1 (0.42) | NPC1RAB9ADGAT1ACSL1 | |
| SCHEMBL10184366 | 0.86 | PDE4A (0.41) | DGAT1ACSL1PDE4APDE4BPDE4C | |
| SCHEMBL10185096 | 0.85 | ACSL1 (0.43) | DGAT1ACSL1 | |
| SCHEMBL10186449 | 0.85 | SMN1; SMN2 (0.46) | NPC1RAB9ADGAT1ACSL1 | |
| SCHEMBL10186419 | 0.85 | PARP15 (0.50) | NR1H4PARP15PARP10PARP2DGAT1 | |
| SCHEMBL10186434 | 0.85 | ATM (0.46) | NPC1RAB9ADGAT1PDE4APDE4B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120046292-A1 | DIACYLETHYLENEDIAMINE COMPOUND | ASTELLAS PHARMA INC. (JP) | 2012-02-23 | — | — | US | disclosed |
| WO-2010122968-A1 | DIACYLETHYLENEDIAMINE COMPOUND | アステラス製薬株式会社 (JP) | 2010-10-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120046292-A1 | DIACYLETHYLENEDIAMINE COMPOUND | DGAT1, DGAT2, DIMT1 | NR1H4 405/4885PARP15 1911/4885PARP10 1704/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.